Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir + ribavirin: insights from a real-life multicenter study
2017; Elsevier BV; Volume: 66; Issue: 1 Linguagem: Inglês
10.1016/s0168-8278(17)31951-7
ISSN1600-0641
AutoresRaffaella Lionetti, I. Lenci, Massimo Siciliano, Maurizio Pompili, Ubaldo Visco‐Comandini, Martina Milana, Chiara Taibi, Marzia Montalbano, Anna Rosa Garbuglia, Paola Begini, Barbara Imperatrice, M. Angélico, Gianpiero D’Offizi,
Tópico(s)Liver Disease and Transplantation
Referência(s)